Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
Summary
Migraine attack is an episodic disorder that affects approximately 12% of the population. Previous studies have shown that 41-48% of migraineur have a combination of patent foramen ovale (PFO). Clinical observational studies have been linking medication therapies which include anticoagulation and anti-platelet therapy with the effectiveness in improving migraine symptoms and reducing the frequency of attacks in patients combined with a PFO. However, it has been unclear whether the effectiveness of anticoagulation or anti-platelet therapy outweigh the conventional migraine medication therapy, as a result, we designed a multi-center randomized clinical trial aiming to examine the effectiveness of anticoagulation versus anti-platelet versus migraine medication therapy in migraine patients with PFO and provide a clinical guidance for migraineur.
Timeline
- Start
- 2022-10-15
- Primary completion
- 2025-03-26
- Completion
- 2025-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirin | Small molecule | 300 mg | Oral |
| Subject | Clopidogrel | Small molecule | 75 mg | Oral |
| Comparator | Metoprolol | Other / unclassified | 25 mg | Oral |
| Subject | Rivaroxaban | Other / unclassified | 20 mg | Oral |